GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
GENMAB A/S
Financials through fiscal 2025, year ended Dec 31, 2025
$38.50+1.50 (+4.05%)
Close on Oct 19, 2026
GENMAB A/S revenue by segment
By business segment
By product or service
By region
| Revenue | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Denmark | 19.78B DKK | 16.05B DKK | 14.51B DKK | 8.42B DKK | 10.11B DKK | 5.37B DKK | 3.03B DKK | 2.37B DKK | 91.9% | +23.2% |
| United States | 902.00M DKK | 380.00M DKK | – | – | – | – | – | – | 4.2% | +137.4% |
| Japan | 841.00M DKK | 41.00M DKK | – | – | – | – | – | – | 3.9% | +1951.2% |
From the segment and revenue-disaggregation notes of Genmab A/S's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.